Viral Vector and Plasmid DNA Manufacturing Market (Type - Lentivirus, Adenovirus, Adeno-Associated Virus (AAV), Plasmid DNA; Application - Gene Therapy, Vaccinology; Disease - Genetic Disorders, Cancer, Infectious Disease; End user - Biotech Companies, Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027


  • Rep Id : XPLREP3799
  • Published On : April, 2019
  • No. of Pages : 199
  • Category : Microbiology
  • Publisher : Transparency Market Research

Viral Vector & Plasmid DNA Manufacturing Market: Overview

This report analyzes the current and future scenario of the global viral vector & plasmid DNA manufacturing market for the period 2019 to 2027. Increase in prevalence and incidence rates of cancer, genetic disorders and infectious diseases, high unmet needs in patients with rare disorders, and raised acceptance for comparatively newer treatment options in developing countries are likely to be major drivers of the global viral vector & plasmid DNA manufacturing market during the forecast period. 

The viral vector & plasmid DNA manufacturing market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on type, application, disease, end-user, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides market attractiveness analysis based on region and market share analysis in terms of key players, thereby presenting a thorough analysis of the overall competitive scenario in the viral vector & plasmid DNA manufacturing market. 

Viral Vector & Plasmid DNA Manufacturing Market: Key Segments

Based on type, the global viral vector & plasmid DNA manufacturing market has been segmented into lentivirus, adenovirus, adeno-Associated Virus (AAV), plasmid DNA, and others. In terms of application, the global viral vector & plasmid DNA manufacturing market has been divided into gene therapy, vaccinology, and others. Based on disease, the market has been segregated into genetic disorders, cancer, infectious disease, and others. In terms of end-user, the market has been bifurcated into biotech companies and research institutes. The market size and forecast for each of these segments have been provided for the period 2019 to 2027, along with their respective CAGR for the forecast period 2017 to 2027, considering 2018 as the base year. 

Viral Vector & Plasmid DNA Manufacturing Market: Regional Outlook

In terms of region, the global viral vector & plasmid DNA manufacturing market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). Market size and forecast for each of these regions and the mentioned countries have been provided for the period 2019 to 2027, along with their respective CAGR for the forecast period 2017 to 2027, considering 2018 as the base year. The research study also covers the competitive scenario in these regions. 

Companies Mentioned in the Report

The report also profiles major players operating in the global viral vector & plasmid DNA manufacturing market based on various attributes, such as company overview, financial overview, product portfolio, business strategies, and recent developments. The players covered in the report include CobraBiologics, Novasep Inc., Cell and Gene Therapy Catapult, Kaneka Eurogentec S.A., FUJIFILM Diosynth Biotechnologies Inc., Spark Therapeutics, Inc. Merck KGaA, uniQure N.V., and Lonza. The global viral vector & plasmid DNA manufacturing market has been segmented as below:

  • Viral Vector & Plasmid DNA Manufacturing Market, by Type
    • Lentivirus
    • Adenovirus
    • Adeno-Associated Virus (AAV)
    • Plasmid DNA
    • Others
  • Viral Vector & Plasmid DNA Manufacturing Market, by Application
    • Gene Therapy
    • Vaccinology
    • Others
  • Viral Vector & Plasmid DNA Manufacturing Market, by Disease
    • Genetic Disorders
    • Cancer
    • Infectious Disease
    • Others
  • Viral Vector & Plasmid DNA Manufacturing Market , by End-user
    • Biotech Companies
    • Research Institutes
  • Viral Vector & Plasmid DNA Manufacturing Market, by Region
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • India
      • China
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • South Africa
      • GCC Countries
      • Rest of Middle East & Africa

Viral Vector And Plasmid Dna Manufacturing Market